P/E Ratio

The P/E ratio of 20.8x means investors are paying $20.80 for every $1 of the company’s annual earnings per share — a common measure of how expensive a stock is relative to its profitability.

Compared to healthcare sector peers, Quest Diagnostics trades below the sector median of 24.7x, placing it in the 32nd percentile, indicating a lower valuation than most companies in its industry. Trend data is not available, as the year-over-year change, quarter-over-quarter change, and trend direction over the last eight quarters are all marked N/A; no shift in valuation can be assessed from the single reported value. The combination of a below-median P/E and the absence of any trend information offers limited insight: the low relative valuation may imply reduced risk of overpricing, but without historical context, it is unclear whether this level is stable or a recent decline. This metric aligns with the NEUTRAL overall verdict, as the below-average multiple does not flag extreme overvaluation or undervaluation, while the lack of trend data prevents a stronger directional conclusion.

Frequently Asked Questions

Closest Sector Peers